Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404549 | 0.85 | PDPK1 (0.41) | GLAPDPK1HCAR2HTTALDH1A1 | |
| SCHEMBL27614783 | 0.82 | SMN1; SMN2 (0.35) | GLAPDPK1POLBUSP2TSHR | |
| SCHEMBL3960641 | 0.81 | GLA (0.37) | GLAPOLBUSP2TSHRSMN1; SMN2 | |
| SCHEMBL3827995 | 0.81 | GLA (0.37) | GLATSHRSMN1; SMN2ALDH1A1HSP90AA1 | |
| SCHEMBL3997044 | 0.79 | DPP4 (0.36) | GLAPDPK1POLBUSP2TSHR | |
| SCHEMBL6633569 | 0.78 | GLA (0.34) | GLASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1070 | 0.76 | SMN1; SMN2 (0.52) | POLBSMN1; SMN2HCAR2ALPLALDH1A1 | |
| SCHEMBL13211644 | 0.72 | PDPK1 (0.45) | PDPK1GDA | |
| SCHEMBL6442196 | 0.72 | CHRM4 (0.39) | BACE1MAPK1 | |
| SCHEMBL6336859 | 0.71 | PDPK1 (0.41) | PDPK1HCAR2GDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253632-B1 | Pyrazolopyramidinone derivatives, their preparation and their use | TOPHARMAN SHANGHAI CO LTD (CN) | 2012-05-23 | — | — | EP | disclosed |
| EP-2253632-A1 | Pyrazolopyramidinone derivatives, their preparation and their use | Topharman Shanghai Co., Ltd. (CN) | 2010-11-24 | — | — | EP | disclosed |
| US-20080318949-A1 | Pyrazolopyrimidinone Derivatives, Their Preparation And Their Use | TOPHARMAN SHANGHAI CO., LTD (CN) | 2008-12-25 | — | — | US | disclosed |
| EP-1961753-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR USE | Topharman Shanghai Co., Ltd. (CN) | 2008-08-27 | — | — | EP | disclosed |
| CN-1281588-C | Novel intermediate for prepn. of pyrazolopyrimidinones | PFIZER (US) | 2006-10-25 | — | — | CN | disclosed |
| CN-1229349-C | Pyridine-3-carboxylic acid derivative | PFIZER (US) | 2005-11-30 | — | — | CN | disclosed |
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6916927-B2 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PFIZER INC. | 2005-07-12 | — | — | US | disclosed |
| EP-1372656-B1 | PYRAZOLO[4,3-D]PYRIMIDINONE COMPOUNDS AS CGMP PDE INHIBITORS | PFIZER LTD (GB) | 2005-06-22 | — | — | EP | disclosed |
| CN-1626516-A | Novel intermediate for prepn. of pyrazolopyrimidinones | PFIZER (US) | 2005-06-15 | — | — | CN | disclosed |
| EP-0977756-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
| WO-1998049166-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 1998-11-05 | — | — | WO | disclosed |
| US-5719283-A | INHIBITORS OF PHOSPHODIESTERASES; CARDIOVASCULAR DISORDERS | PFIZER INC. (US) | 1998-02-17 | — | — | US | disclosed |
| CN-1028758-C | Pyrazolopyrimidinone antianginal agents | PFIZER (US) | 1995-06-07 | — | — | CN | disclosed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5346901-A | Treatment of angina, hypertension, heart failure and atherosclerosis | PFIZER INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
| CN-1057464-A | Pyrazolopyrimidinoneantianginal antianginal agents | PFIZER (US) | 1992-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318949-A1 | Pyrazolopyrimidinone Derivatives, Their Preparation And Their Use | PDE5A, PDE3A, PDE3B | GLA 2829/4885PDPK1 59/4885POLB 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.